Company profile: Bioquell
1.1 - Company Overview
Company description
- Provider of biodecontamination systems and services specializing in Hydrogen Peroxide Vapor technology to eliminate bacteria, viruses, fungi, and spores. Products include Bioquell Hydrogen Peroxide Vapour Decontamination (35% H2O2 vapor for surface and airborne pathogen elimination), Rapid Bio-Decontamination Service, ProteQ automated room decontamination, and Qube isolators for sterility testing.
Products and services
- Bioquell Hydrogen Peroxide Vapour Decontamination: Engineers a 35%-concentration Hydrogen Peroxide Vapor bio-decontamination system eliminating surface and airborne pathogens—bacteria, viruses, fungi, and spores
- Bioquell ProteQ: Architects an automated Hydrogen Peroxide Vapor room-decontamination system delivering high-level disinfection, targeting problematic bacteria, viruses, fungi, and spores
- Bioquell Rapid Bio-Decontamination Service (RBDS): Delivers scheduled or emergency Hydrogen Peroxide Vapor decontamination for various environments, eliminating problematic bacteria, viruses, fungi, and spores
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bioquell
Ashvattha Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage precision nanomedicines and PET imaging agents, developing D-4517.2 for wet AMD and DME, OP-801 targeting CNS macrophages/microglia as a biomarker of neuroinflammation, OP-101 to modulate inflammatory cell activity in severe COVID-19 and other inflammatory diseases, and CSF1R Dendranib, a CSF1R tyrosine kinase inhibitor for multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ashvattha Therapeutics company profile →
Durata Therapeutics
HQ: United States
Website
- Description: Provider of late-stage clinical development of novel antibiotics for infectious diseases, focused on Vicuron’s antibiotic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Durata Therapeutics company profile →
GenePOC
HQ: Canada
Website
- Description: Provider of accurate, cost-effective molecular solutions to detect pathogen genes, featuring a simple, stand-alone system for prevention and early detection of infectious diseases based on unique microfluidic technology; a privately owned member of Debiopharm Group.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenePOC company profile →
Taxis Pharmaceuticals
HQ: United States
Website
- Description: Provider of anti-infective pharmaceuticals focused on discovery and development of novel agents, including TXA709, an oral anti-MRSA agent targeting the FtsZ bacterial cell division protein (completed Phase I), and efflux pump inhibitors for Gram-negative MDR pathogens by inhibiting resistance efflux pumps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Taxis Pharmaceuticals company profile →
Genticel
HQ: France
Website
- Description: Provider of therapeutic vaccines and innovative immunotherapies to treat virus infections and virus-induced diseases, with an initial focus on HPV and HPV-induced conditions, including prevention of cervical cancer in HPV-infected women.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genticel company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bioquell
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bioquell
2.2 - Growth funds investing in similar companies to Bioquell
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bioquell
4.2 - Public trading comparable groups for Bioquell
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →